- Home
- MITQ vs XAIR Comparison
MITQ vs XAIR Comparison
Compare MITQ & XAIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MITQ | XAIR |
|---|---|---|
| Founded | N/A | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Medical/Dental Instruments |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9M | 5.4M |
| IPO Year | 2019 | 2015 |
Fundamental Metrics
Financial Performance| Metric | MITQ | XAIR |
|---|---|---|
| Price | $0.61 | $0.46 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 90.0K | ★ 266.0K |
| Earning Date | 05-15-2026 | 06-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 62.09 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $20,139,000.00 | $3,705,000.00 |
| Revenue This Year | N/A | $122.00 |
| Revenue Next Year | N/A | $58.15 |
| P/E Ratio | $58.00 | ★ N/A |
| Revenue Growth | N/A | ★ 219.67 |
| 52 Week Low | $0.42 | $0.15 |
| 52 Week High | $1.66 | $3.78 |
Technical Indicators
Market Signals| Indicator | MITQ | XAIR |
|---|---|---|
| Relative Strength Index (RSI) | 47.99 | 44.11 |
| Support Level | $0.57 | $0.41 |
| Resistance Level | $0.64 | $0.59 |
| Average True Range (ATR) | 0.04 | 0.05 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 53.48 | 42.29 |
Price Performance
Historical ComparisonAbout MITQ Moving iMage Technologies Inc.
Moving iMage Technologies Inc is engaged in providing designed equipment as well as other off the shelf cinema products needed for contemporary cinema requirements. It offers technical, design and consulting services such as custom engineering, systems design, integration and installation and digital technology, as well as software solutions for operations enhancement and theatre management.
About XAIR Beyond Air Inc.
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.